Medical Simulation Medical Graphic
Medical Animation | MOA | Medical Illustration | Holo 3D | General 3D | Video Game Development | Contact

Biotechnology Animations – Biotechnology Illustrations

Clinical Animations / Trial Animations

Clinical Studies Animated Method of Action Video

Medical Animation Studio produces clinical animations and clinical illustrations.  Custom 3d trail illustrations and clinical illustrations for e learning can also be produced.   Biotechnology animations and biotechnology illustrations created for biotech companies and biotechnology marketing companies.
Biotechnology animated method of action video. 
Dr Nano
Researchers identify biological indicator of response to new ovarian cancer drug
Researchers have found a way of identifying which ovarian cancer patients are likely to respond well to a new anti-cancer drug called rucaparib.
Early results show response to new drug in patients with lymphomas and advanced solid tumours
Patients with B-cell Non-Hodgkin lymphomas and advanced solid tumours have responded to a new drug that is being tested for the first time in humans in a phase I clinical trial.
New long-term analyses of Celgene's OTEZLA® (apremilast) in psoriatic arthritis presented at ACR 2014
Celgene Corporation has announced that results from long-term (104-week) efficacy and safety analyses of OTEZLA® (apremilast) from the open-label phase of two PALACE phase III clinical trials...
Results announced from six Phase 3 trials showing that alirocumab significantly reduced LDL cholesterol
Sanofi and Regeneron Pharmaceuticals, Inc. has announced new detailed positive results from six Phase 3 ODYSSEY trials that showed alirocumab significantly reduced low-density lipoprotein...
Three drugs may be better than one for certain patients with advanced colorectal cancer
Patients with a form of advanced colorectal cancer that is driven by a mutated version of the BRAF gene have limited treatment options available.
Half of patients do not take meds as prescribed, yet no effective interventions in place
A review examines previous trials aimed at tackling poor patient adherence to meds and finds that studies so far have been poorly designed, yielding 'inconsistent' results.
Data show Vectra DA is better predictor of joint damage in rheumatoid arthritis patients
Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc., has presented new data that showed Vectra® DA is a better predictor of radiographic progression over two years than...
Results of large cholesterol-lowering/outcomes study revealed at AHA
Merck, known as MSD outside the United States and Canada, has announced that the investigational IMPROVE-IT study met its primary and all secondary composite efficacy endpoints.
Trial results show treatment-resistant advanced non-small cell lung cancer responds to new drug, rociletinib
A new drug that targets not only common cancer-causing genetic mutations in patients with non-small cell lung cancer (NSCLC), but also a form of the mutation that causes resistance to treatment...
New data from PARADIGM-HF study for heart failure drug LCZ696 released
New data from PARADIGM-HF, the largest-ever heart failure study showed that LCZ696 has the potential to change the course of the disease for patients with HFrEF.
Long-term data showing efficacy and safety of investigational cholesterol-lowering medication evolocumab announced
Amgen has announced new data from three separate analyses of Phase 2 and 3 studies evaluating evolocumab, a novel investigational low-density lipoprotein cholesterol (LDL-C)-lowering medication.
New data presented on efficacy of Simponi® (golimumab) in treating patients with active non-radiographic axial spondyloarthritis
MSD (Merck Sharp and Dohme) announced findings from the GO-AHEAD study[1] showing that patients with active non-radiographic axial spondyloarthritis (nr-AxSpA) treated with injections of...
Cheap anti-malaria drug shows promise against colorectal cancer
Artesunate - a cheap and commonly used anti-malaria drug - shows promising results in a pilot study that tested it on colorectal cancer patients before tumor-removal surgery.
Gout: data from Phase III studies of lesinurad in combination with allopurinol
AstraZeneca has presented top-line results of two pivotal Phase III trials investigating the potential of lesinurad, a selective uric acid re-absorption inhibitor (SURI), when used in combination...
First demonstration of anti-cancer activity for AG-120, an inhibitor of the IDH1 mutation, in patients with advanced leukaemia
A phase I trial of the first drug designed to inhibit the cancer-causing activity of a mutated enzyme known as isocitrate dehydrogenase (IDH) 1, which is involved in cell metabolism, has shown...
WindowsFlashQuicktime
Request Demo Reel DVD
Related Medical Animation Links

Copyright © 2014
Content Management / Website Design by Tresware